Olema Pharmaceuticals Inc (OLMA) FinancialsOLMAOlema Pharmaceuticals Inc

Evaluating the bottom line, Olema Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -52.74%, provide a clear picture of how effectively OLMA converts its operational activities into shareholder value.

In the context of the broader market, OLMA competes directly with industry leaders such as NVCT and ZVRA. With a market capitalization of $594.98M, it holds a significant position in the sector. When comparing efficiency, OLMA's gross margin of N/A stands against NVCT's N/A and ZVRA's 95.36%. Such benchmarking helps identify whether Olema Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Olema Pharmaceuticals has consistently reported losses, with a net income of -$63.2 million in Q2 2026 and an EPS of -0.61 for the same quarter. The company's current ratio is strong at 8.86, indicating good liquidity, but the overall financial performance remains concerning due to ongoing losses.